Tranexamic acid (TXA) is a synthetic derivative of the amino acid lysine that inhibits
fibrinolysis by blocking the lysine-binding site on plasminogen. The Clinical Randomization
of an Antifibrinolytic in Significant Haemorrhage 2 (CRASH-2) study examined the effects
of early administration of a short course of TXA in trauma patients. Publication of
this landmark study and the data regarding the safety profile of TXA have led to its
liberal use for many clinical situations in which hemorrhage poses an immediate threat
to life. However, the evidence to support this practice has been either scant or absent.
In this issue, we summarize recently published evidence to help guide TXA use in an
evidence-based manner.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Air Medical JournalAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Biography
Russell D. MacDonald, MD, MPH, FCFP, FRCPC, is the medical director at Ornge Transport Medicine; medical director at Toronto Paramedic Services; an associate professor in the Faculty of Medicine at the University of Toronto; and an attending staff member at Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada. He can be reached at [email protected].
Article info
Publication history
Published online: December 28, 2020
Identification
Copyright
© 2020 Air Medical Journal Associates. Published by Elsevier Inc. All rights reserved.
